Johns Hopkins University
The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.
Inclusion Criteria: Disease Characteristics 1. Have a BMI ≥30 kg/m2 or ≥27 kg/m2 * previously diagnosed with at least one obesity-related comorbidity: 2. Have at least one self-reported unsuccessful dietary effort to lose body weight 3. Meet Diagnostic and Statistical Manual (DSM)-5 criteria for Binge Eating Disorder (BED) as diagnosed by the Eating Disorder Examination interview and confirmed by binge-eating diaries that is moderate or greater in severity (4 or more episodes per week) Participant Characteristics 4. Are 18 years of age or older 5. Participants assigned female at birt…
Tirzepatide
Lisdexamfetamine dimesylate
Guided self-help cognitive behavioral therapy
Placebo (oral)
Placebo (injection)
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.